Denmark
· Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 51.43 billion. The enterprise value is 42.62 billion.
| Market Cap | 51.43B |
| Enterprise Value | 42.62B |
Important Dates
The next estimated earnings date is Thursday, February 20, 2025.
| Earnings Date | Feb 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 70.65 million shares outstanding. The number of shares has increased by 15.69% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 70.65M |
| Shares Change (YoY) | +15.69% |
| Shares Change (QoQ) | +12.72% |
| Owned by Insiders (%) | 0.27% |
| Owned by Institutions (%) | 50.44% |
| Float | 60.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.79 |
| P/TBV Ratio | 5.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -40.49 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -60.33 |
Financial Position
The company has a current ratio of 35.49, with a Debt / Equity ratio of 0.04.
| Current Ratio | 35.49 |
| Quick Ratio | 35.20 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.55 |
| Interest Coverage | -38.58 |
Financial Efficiency
Return on equity (ROE) is -19.67% and return on invested capital (ROIC) is -12.44%.
| Return on Equity (ROE) | -19.67% |
| Return on Assets (ROA) | -11.81% |
| Return on Capital (ROIC) | -12.44% |
| Revenue Per Employee | 257,953 |
| Profits Per Employee | -3.53M |
| Employee Count | 253 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 122.31 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +99.89% in the last 52 weeks. The beta is 0.55, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +99.89% |
| 50-Day Moving Average | 781.04 |
| 200-Day Moving Average | 771.42 |
| Relative Strength Index (RSI) | 41.52 |
| Average Volume (20 Days) | 234,180 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 76.87 million and -1.05 billion in losses. Loss per share was -16.62.
| Revenue | 76.87M |
| Gross Profit | -627.26M |
| Operating Income | -1.12B |
| Pretax Income | -1.06B |
| Net Income | -1.05B |
| EBITDA | -1.11B |
| EBIT | -1.12B |
| Loss Per Share | -16.62 |
Balance Sheet
The company has 8.48 billion in cash and 389.49 million in debt, giving a net cash position of 8.81 billion or 124.77 per share.
| Cash & Cash Equivalents | 8.48B |
| Total Debt | 389.49M |
| Net Cash | 8.81B |
| Net Cash Per Share | 124.77 |
| Equity (Book Value) | 8.88B |
| Book Value Per Share | 125.74 |
| Working Capital | 8.47B |
Cash Flow
In the last 12 months, operating cash flow was -690.82 million and capital expenditures -15.60 million, giving a free cash flow of -706.42 million.
| Operating Cash Flow | -690.82M |
| Capital Expenditures | -15.60M |
| Free Cash Flow | -706.42M |
| FCF Per Share | -10.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,451.03% |
| Pretax Margin | -1,375.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.69% |
| Shareholder Yield | -15.69% |
| Earnings Yield | -2.28% |
| FCF Yield | -1.37% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 31.29.
| Altman Z-Score | 31.29 |
| Piotroski F-Score | n/a |